Celltrion’s YUFLYMA gains full FDA interchangeability: What it means for U.S. biosimilar market

In a major regulatory milestone for the biosimilar drug landscape, South Korea-based Celltrion, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted expanded interchangeability designation for YUFLYMA® (adalimumab-aaty). This designation now encompasses all approved dosage forms and strengths of YUFLYMA, including prefilled syringes (40mg) and autoinjectors (40mg and 80mg). This marks a significant development in Celltrion’s long-term strategy to penetrate the U.S. immunology market and challenge the entrenched dominance of AbbVie’s Humira®.

Why Does YUFLYMA’s Full Interchangeability Status Matter?

Interchangeability designation allows pharmacists to substitute a biosimilar for the reference product without consulting the prescriber, subject to state pharmacy laws. This regulatory milestone significantly enhances YUFLYMA’s market access, placing it on par with Humira across all delivery formats. Previously, Celltrion had only received FDA interchangeability for YUFLYMA’s 20mg and 80mg prefilled syringes. With the latest FDA nod, the coverage now includes the 40mg prefilled syringe and both 40mg and 80mg autoinjectors.

This means that for patients and healthcare systems, switching between Humira and YUFLYMA becomes easier and more cost-effective, potentially translating into higher adoption rates in an increasingly competitive biosimilar ecosystem. Celltrion aims to leverage this expanded interchangeability to position YUFLYMA as a leading alternative to Humira, targeting a broad range of autoimmune and inflammatory conditions.

How Does YUFLYMA Compare to Humira in Clinical Efficacy and Safety?

YUFLYMA is a high-concentration, citrate-free biosimilar of Humira designed to reduce injection volume and minimize discomfort for patients. The drug is indicated for multiple inflammatory conditions, including rheumatoid arthritis, Crohn’s disease, plaque psoriasis, ulcerative colitis, and juvenile idiopathic arthritis, among others. Clinical data submitted to support its interchangeability included a pivotal Phase III study on patients with moderately to severely active plaque psoriasis. Results presented at the 2024 European Academy of Dermatology and Venereology conference in the Netherlands confirmed comparable outcomes between YUFLYMA and Humira in pharmacokinetics, efficacy, safety, and immunogenicity.

The FDA’s interchangeability decision was influenced by this rigorous study design and favorable outcomes, signaling a high level of confidence in YUFLYMA’s clinical performance. For payers, providers, and patients, this adds a layer of reassurance when considering biosimilar switches.

What Are the Safety Considerations and Risks Associated with YUFLYMA?

As with all tumor necrosis factor (TNF) blockers, YUFLYMA carries safety risks, including serious infections, malignancies, hypersensitivity reactions, and reactivation of hepatitis B. Notably, infections such as tuberculosis, invasive fungal infections, and opportunistic pathogens have been reported. Malignancies including lymphomas and leukemias, particularly in pediatric populations or those on concomitant immunosuppressants, remain a critical concern.

Additional complications can include new or worsening congestive heart failure, hematologic abnormalities like pancytopenia, and rare autoimmune responses such as lupus-like syndromes. Celltrion’s safety labeling mirrors that of Humira, ensuring that healthcare providers remain vigilant and that patients are well-informed about risks before initiating therapy.

How Has YUFLYMA Been Positioned Commercially in the U.S. Market?

Since its launch in July 2023, YUFLYMA has been available in multiple strengths and delivery mechanisms, including 20mg, 40mg, and 80mg prefilled syringes and 40mg and 80mg autoinjectors. Celltrion USA offers both branded and unbranded versions to provide flexibility in pricing and accessibility. This dual-pricing approach targets multiple patient demographics, from those covered by commercial insurance to price-sensitive populations, such as Medicare and Medicaid beneficiaries.

The commercial strategy reflects Celltrion’s broader objective to capture market share from Humira, which until recently had enjoyed virtual monopoly status in the adalimumab segment. With multiple biosimilars now competing in the space, interchangeability has emerged as a key differentiator. The expansion of this designation helps YUFLYMA stand out among rivals such as Amgen’s Amjevita® and Boehringer Ingelheim’s Cyltezo®.

What Does This Mean for the U.S. Biosimilar Industry and Patients?

The expanded interchangeability designation for YUFLYMA represents a broader trend in the U.S. pharmaceutical industry toward embracing biosimilar alternatives. Historically, biosimilar uptake in the U.S. has lagged behind Europe due to regulatory conservatism, prescriber hesitancy, and entrenched brand loyalty. However, recent policy changes and payer incentives have begun to shift the landscape.

For patients, particularly those managing chronic autoimmune conditions, this shift could translate into lower drug costs, better adherence due to reduced injection discomfort, and improved treatment outcomes. For the industry, it signals increasing confidence in biosimilar development and a gradual erosion of the branded biologics’ market exclusivity.

From a policy standpoint, expanded interchangeability also aligns with FDA and Centers for Medicare & Medicaid Services (CMS) initiatives aimed at curbing prescription drug spending. As these programs gain momentum, manufacturers like Celltrion are well-positioned to benefit from first-mover advantages in the interchangeable biosimilars category.

How Does Celltrion’s Broader Portfolio Support Its U.S. Ambitions?

Celltrion USA, the U.S. arm of Celltrion, Inc., has established itself as a prominent player in the biosimilar market with a robust product pipeline. Besides YUFLYMA, its portfolio includes FDA-approved biosimilars such as INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), and AVTOZMA® (tocilizumab-anho), among others. These drugs target immunology, oncology, hematology, and endocrinology indications, enabling the company to diversify its U.S. presence across multiple therapeutic verticals.

In parallel, Celltrion is advancing novel biologics such as ZYMFENTRA® (infliximab-dyyb), adding to its strategic vision of not only competing in biosimilars but also shaping the next generation of biologic therapeutics. This hybrid approach blends cost-effective biosimilar development with innovation, an area where it may gain further competitive ground.

What Comes Next for Celltrion and YUFLYMA?

The expanded interchangeability status paves the way for YUFLYMA to significantly scale its U.S. footprint in 2025 and beyond. Industry observers anticipate that major pharmacy benefit managers (PBMs) and hospital systems will take note of the updated designation, potentially integrating YUFLYMA more extensively into formularies. As healthcare systems continue to prioritize value-based care, high-quality biosimilars like YUFLYMA are likely to see accelerated adoption.

For Celltrion, the journey does not end here. Continued investment in U.S. commercial infrastructure, physician education, and patient support programs will be essential to maximizing the potential of YUFLYMA and the broader biosimilar pipeline. The next phase will test whether interchangeability can translate into real-world market traction—a question that could reshape biosimilar strategies across the pharmaceutical industry.